NEXVET ANNOUNCES US$31.5 MILLION FINANCING

NEXVET ANNOUNCES US$31.5 MILLION FINANCING U.S. Institutional Investors Lead Oversubscribed Round To Advance Monoclonal Antibody Clinical Programs For Companion Animal Health MELBOURNE, Australia–April 16, 2014 –Nexvet Biopharma, a leading veterinary biologic drug developer, today announced the closing of its US$31.5 million Series B round of financing. Top–‐tier U.S.–‐based institutional investors Farallon Capital Management, LLC, Adage […]

Nexvet shares promise of new treatments for chronic illness in companion animals with BSAVA Congress 2014

Link here. BIRMINGHAM, United Kingdom –‐ April 3, 2014 – Nexvet Biopharma, a leading veterinary biologic drug developer, today announced that its Chief Scientific Officer, Professor David Gearing, will be presenting at the British Small Animal Veterinary Association (BSAVA) Congress 2014. The BSAVA Congress runs from April 3 – 6 and is one of Europe’s largest […]

Nexvet unveils clinical data supporting its novel pain treatment for dogs

04 December, 2013. Link here. Leading veterinary biologic drug developer Nexvet Biopharma (Nexvet) today announced promising clinical data in support of its novel compound NV-01 for treating acute and chronic pain in dogs.